Bicara Therapeutics (NASDAQ:BCAX) Trading Down 2.9% – Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) was down 2.9% on Thursday . The company traded as low as $16.91 and last traded at $16.91. Approximately 43,480 shares changed hands during trading, a decline of 90% from the average daily volume of 418,549 shares. The stock had previously closed at $17.42.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Rodman & Renshaw started coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective on the stock. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective for the company. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright began coverage on Bicara Therapeutics in a report on Friday, December 6th. They issued a “buy” rating and a $42.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $43.00.

Bicara Therapeutics Trading Down 1.4 %

The business has a fifty day simple moving average of $20.10.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds have recently made changes to their positions in the company. Cinctive Capital Management LP bought a new position in Bicara Therapeutics during the 3rd quarter valued at approximately $229,000. Barclays PLC bought a new position in shares of Bicara Therapeutics during the third quarter valued at $255,000. Jane Street Group LLC purchased a new position in shares of Bicara Therapeutics in the 3rd quarter worth about $309,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Bicara Therapeutics in the 3rd quarter worth about $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Bicara Therapeutics in the 3rd quarter worth about $462,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.